POSTN and head and neck cancer: Nonetheless, rapamycin and other FDA approved rapalogs constitute a viable therapeutic strategy for diseases and pathologies associated with increased levels of Periostin, including colorectal, prostate, breast, and head and neck cancers [59-62].